Trial
NCT06468605
Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Duke University
Collaborators
—
Condition
Recurrent or Progressive High-grade Glioma
Intervention
JCXH-211
Why stopped
Immorna, the funder withdrew the funds to run this study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-23